Category
61 releases
Differentiated trispecific TIGIT-Fc ligand-trap strategy aims to address CD226 downregulation, a potential limitation of conventional anti-TIGIT…
Company to hold a conference call at 8AM ET on November 5, 2026 to review results and provide a corporate update SHELTON, Conn., Oct. 30, 2026 —…
IL-23 inhibitor approved exclusively for healthcare provider-administered treatment Expands use of ILUMYA beyond moderate-to-severe plaque psoriasis…
$600K+ investment leverages combination of FDA approved treatments to overcome drug resistance in EGFR-positive lung cancer WASHINGTON, Oct. 28, 2026…
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today…
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an…
Designation recognizes the potential of Neurapheresis to offer advantages over existing treatment options following aneurysmal subarachnoid…
The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd)…
INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often…
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2026 of $1.73 per share on outstanding…
A new drug is effective at decreasing recurrence of and death from endometrial cancer, a landmark international study shows. The drug, called…
KEYNOTE-C93/GOG-3064/ENGOT-en15 results presented in the ESMO 2026 Presidential Symposium and published simultaneously in The Lancet MIAMI BEACH,…
Median overall survival of 12 months with RBS2418 monotherapy in subjects with heavily pretreated tumors that express ENPP1 and cGAS proteins…
A study coauthored by Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio N. Gordan, MD is among the…
Presented at the NORD Breakthrough Summit, the findings show EDS patients wait a median of nearly eight years for a diagnosis, a delay that…
Vantive plans to expand its HomeAdvantage offering with the next-generation Avira automated peritoneal dialysis cycler, which is progressing through…
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a…
Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to…
NASDAQ | TSX: ACB Alberta Securities Commission dismisses Curaleaf's application concerning Aurora's ATM program. Curaleaf's unsuccessful application…
